Miragen Therapeutics Inc (OQ:MGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 6200 Lookout Rd
BOULDER CO 80301-3319
Tel: N/A
Website: www.miragen.com
IR: See website
<
Key People
Jeffrey S. Hatfield
Independent Chairman of the Board
William S. Marshall
President, Chief Executive Officer, Director
Jason A. Leverone
Chief Financial Officer, Treasurer, Secretary
Business Overview
Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
Financial Overview
For the fiscal year ended 31 December 2019, Miragen Therapeutics Inc revenues decreased 47% to $4.5M. Net loss increased 28% to $41.9M. Revenues reflect Collaboration revenue decrease of 42% to $4.3M, Grant revenue decrease of 85% to $153K. Higher net loss reflects Research and Development - Balancing increase of 7% to $31.1M (expense), General and administrative - Balancing v increase of 5% to $9.1M (expense).
Employees: 45 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $6.21M as of Dec 31, 2019
Annual revenue (TTM): $4.46M as of Dec 31, 2019
EBITDA (TTM): -$41.69M as of Dec 31, 2019
Net annual income (TTM): -$41.87M as of Dec 31, 2019
Free cash flow (TTM): -$36.14M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 53,066,099 as of Mar 2, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization